Skip to main content
. Author manuscript; available in PMC: 2013 Nov 7.
Published in final edited form as: Lancet. 2012 Nov 22;381(9863):10.1016/S0140-6736(12)61857-1. doi: 10.1016/S0140-6736(12)61857-1

Figure 2.

Figure 2

Survival following treatment with regorafenib or placebo. (A) Kaplan–Meier curves for progression-free survival (PFS) per central review (primary endpoint, final analysis). (B) Kaplan–Meier curves for overall survival (OS; interim analysis)